BioSpace News Archive

Career Advice

The Most Important Things to Do When You Go on the Job Market

Are you ready to look for a new job? If you have made the decision to put yourself on the job market, there are a few things that you need to do right away to get yourself ready for the process.

September 24, 2018
·
4 min read
·
Editorial Staff
Deals

A Look at 7 Upcoming and Recently Announced Biotech IPOs

According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.

September 24, 2018
·
3 min read
·
Mark Terry
Business

Tesaro Highlights Benefits of Maintenance Therapy Zejula During Ovarian Cancer Awareness Month

Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.

September 24, 2018
·
4 min read
·
Alex Keown
Drug Development

Nothing Fishy Here: Amarin’s Fish Oil-Based Drug Dramatically Reduces Cardiovascular Risk

Physicians have long recommended fish oil to patients with high cholesterol and triglycerides, even though the scientific studies on it are mixed. Amarin developed a drug called Vascepa, which derives from a purified component of fish oil called eicosapentaenoic acid (EPA).

September 24, 2018
·
3 min read
·
Mark Terry
Policy

Aridis Pharma Deepens Patents for Infectious Disease Therapies

Aridis Pharmaceuticals, headquartered in San Jose, California, announced it had added broad patent coverage of two of its product candidate monoclonal antibodies.

September 24, 2018
·
3 min read
·
Mark Terry
Drug Development

AstraZeneca’s Diabetes Drug Farxiga Decreases Risk of Cardiovascular Disease

AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).

September 24, 2018
·
2 min read
·
Mark Terry
Drug Development

Epizyme Announces Removal of FDA’s Partial Ban in Phase II Clinical Trials

Epizyme, an innovative epigenetic therapy development company, announced this morning that the U.S. Food and Drug Administration has removed their former partial clinical hold reported in April of this year.

September 24, 2018
·
3 min read
·
Elizabeth Glasure
Business

After Stumbling with Waylivra, Akcea Therapeutics’ Lipid Drug Shows Promise

Akcea Therapeutics, based in Cambridge, Massachusetts, and Ionis Pharmaceuticals, headquartered in Carlsbad, California, released positive topline data from a Phase II trial of AKCEA-APO(a)-LRx in cardiovascular disease and lipoprotein(a).

September 24, 2018
·
3 min read
·
Mark Terry
Policy

Pharma Companies React to Employers and Health Plans Excluding New Therapies Based on Cost

Recently, a few companies and government programs have decided to enact their own plans that they believe will help bring down the cost of new therapies. Pharmaceutical companies have begun asserting their positions on the topic.

September 24, 2018
·
3 min read
·
Sasha Mortimer
BioCapital

DKT International Advances the Goals of World Contraception Day, Every Day

DKT International is proud to share in the goals of World Contraception Day, which, according to the World Health Organization (WHO), are: (1) to acknowledge that “access to preferred contraceptive methods for women and couples -

September 24, 2018
·
4 min read